The rationale for this therapeutic strategy is that inhibition of LINK-A expression by LINK-A LNAs restores the antigen presentation pathway of cancer cells, thereby improving the sensitivity of cancer to ICB treatment. This evidence concerns the gene LINC01139 and cancer.